All In MedTech

Device Trial Radar · NCT05507528

Evaluation of the Safety and Efficacy of REBORN System for Lipolysis Treatment

EVALUATION OF THE SAFETY AND EFFICACY OF REBORN LED SYSTEM FOR NON-INVASIVE LIPOLYSIS TREATMENT

Last checked: Nov 20, 2026Latest source record: Feb 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

107

Actual

Start

Jun 30, 2022

Primary completion

Nov 11, 2023

Study completion Nov 11, 2023

Sponsor

Lead sponsor
Lightfective LtdNot on our public-company list
Sponsor type
Industry
First posted
Aug 19, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Lightfective ReBorn System is intended for non-invasive lipolysis of the flanks in individuals with a Body Mass Index (BMI) of 30 or less. The device is intended to affect the appearance of visible fat bulges in the flanks.

Conditions

  • LIPOLYSIS

Interventions

  • reborn treatmentDevice

    Fat reduction treatments with the ReBorn LED System visit - include the treatment procedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Fat reductionTime frame: 20 weeks
  2. Blinded reviewers evaluationTime frame: 20 weeks

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Tennessee Clinical Research Center

    Tennessee City, Tennessee

  • Herzelia Medical Center - Tal Nachliely clinic

    Kiryat Bialik, Israel

  • rabin medical center - campus Hasharon

    Petah Tikva, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.